Patents Examined by Anoop Singh
  • Animal models and therapeutic molecules
    Patent number: 9434782
    Abstract: The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanized antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: September 6, 2016
    Assignee: Kymab Limited
    Inventors: Allan Bradley, E-Chiang Lee, Qi Liang, Wei Wang, Glenn Friedrich
  • Modified release dosage form comprising desvenlafaxine or salts thereof
    Patent number: 9408814
    Abstract: The present invention refers to a modified release pharmaceutical composition comprising desvenlafaxine or salts thereof, a release rate modifying system that controls the release of active agent(s) in both acidic and basic environments. A process of making and method of using the above-described composition is also disclosed.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: August 9, 2016
    Assignee: WOCKHARDT LIMITED
    Inventors: Girish Kumar Jain, Premchand Dalichandji Nakhat
  • Carrageenan mixtures useful as cosmetic ingredients and hair styling gels comprising them
    Patent number: 9402798
    Abstract: This invention provides a carrageenan mixture comprising about 60% to about 95% by weight of iota-carrageenans and about 5% to about 25% by weight of lambda-carrageenans, which is useful as an ingredient of a cosmetic formulation such as a fully natural hair styling gel being free from synthetic polymers.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: August 2, 2016
    Assignee: Cargill, Incorporated
    Inventors: Christel Beaumer, Gertrudis Maria Juliaan Haest, Claudine Lefrancois
  • Induced pluripotent stem cells derived from human pancreatic beta cells
    Patent number: 9394523
    Abstract: A method of generating pluripotent stem cells is described. The method comprises: (a) expanding human pancreatic beta cells; and subsequently (b) generating induced pluripotent stem (iPS) cells from the human pancreatic beta cells. Methods of redifferentiating the iPS cells into particular cell types are also disclosed. Uses of the cell populations are also described.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: July 19, 2016
    Assignees: Ramot at Tel-Aviv University Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Shimon Efrat, Nissim Benvenisty
  • Differentiation of human embryonic stem cells into single hormonal insulin positive cells
    Patent number: 9388386
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides methods to produce a population of cells, wherein greater than 10% of the cells in the population express markers characteristic of single hormonal pancreatic beta cells.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: July 12, 2016
    Assignee: Janssen Biotech, Inc.
    Inventor: Alireza Rezania
  • Methods of producing hybrid antibodies
    Patent number: 9388446
    Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: July 12, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, George D. Yancopoulos, Margaret Karow, Lynn Macdonald, Sean Stevens, Aris N. Economides, David M. Valenzuela
  • Confectionery products and process for obtaining them
    Patent number: 9386783
    Abstract: Agglomerates comprising calcium-hydrocolloid-composite materials and at least one sugar alcohol, as well of methods for preparing the agglomerates and various applications thereof.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: July 12, 2016
    Assignees: SÜDZUCKER AKTIENGESELLSCHAFT MANNHEIM/OCHSENFURT, HENKEL AG & CO. KGAA
    Inventors: Stephan Hausmanns, Tillmann Dörr, Jörg Kowalczyk, Rainer Kliss, Tilo Poth, Badr Nfissi, André Schirlitz
  • Methods of producing hybrid antibodies
    Patent number: 9382567
    Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: July 5, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, George D. Yancopoulos, Margaret Karow, Lynn Macdonald, Sean Stevens, Aris N. Economides, David M. Valenzuela
  • Use of stem cells to generate inner ear cells
    Patent number: 9375452
    Abstract: This invention relates generally to methods and compositions for inducing stem cell or progenitor cell differentiation, and more particularly to methods and compositions for inducing differentiation of stem cells and/or progenitor cells into cells that function within the inner ear.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 28, 2016
    Assignee: Massachusetts Eye & Ear Infirmary
    Inventors: Albert Edge, Stefan Heller
  • Method for producing intestinal cells
    Patent number: 9376665
    Abstract: An object of the present invention is to provide a method of producing intestinal cells by use of pluripotent stem cells as a starting material. According to the present invention, provided is a method of producing intestinal cells, comprising the steps of: (A) inducing differentiation of pluripotent stem cells into definitive endoderm cells; and (B) culturing the definitive endoderm cells in the presence of (2?Z,3?E)-6-bromoindirubin-3?-oxime (BIO) and N-[(3,5-difluorophenyl)acetyl]-L-Ala-2-phenyl-L-Gly-tert-butyl-OH (DAPT) to thereby induce differentiation of the definitive endoderm cells into intestinal cells.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: June 28, 2016
    Assignees: National University Corporation Kumamoto University, LSIP, LLC
    Inventors: Shoen Kume, Soichiro Ogaki, Nobuaki Shiraki, Kazuhiko Kume
  • Genetically modified mice that produce hybrid antibodies
    Patent number: 9371553
    Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: June 21, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, George D. Yancopoulos, Margaret Karow, Lynn Macdonald, Sean Stevens, Aris N. Economides, David M. Valenzuela
  • Method for the production of permanent human cell lines
    Patent number: 9371512
    Abstract: The present invention relates to a permanent human cell line comprising a nucleic acid sequence for the adenoviral gene functions E1A and E1B and the nucleic acid sequence for the SV40 large T-antigen or the Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1). Further, the present invention relates to a method for transient expression of recombinant polypeptides and proteins in said permanent human cell line.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: June 21, 2016
    Assignee: CEVEC PHARMACEUTICALS GMBH
    Inventors: Gudrun Schiedner, Christoph Volpers
  • 5-aminolevulinic acid prodrugs for use in photodynamic therapy and photodynamic diagnosis
    Patent number: 9371275
    Abstract: There is provided a compound of Formula (I) and salts thereof, where R1 is an oxime or an alkylated oxime; the alkylated oxime comprises a linear or branched alkyl group of length C1 to C5; and R2 are each independently (a) an unsubstituted or substituted linear or branched alkyl group of chain length C1-7, (b) an aryl substituted alkyl group, where the aryl group is substituted, (c) an alkoxy substituted alkyl group, where the alkoxy group is substituted by a methoxy group or an alkoxy group substituted with an alkoxy group, or (d) an H atom, where the substituents in (a) and (b) are hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, nitro, oxo or fluoro groups. The compounds may be used as a medicament.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: June 21, 2016
    Assignee: SWEDISH PHARMA AB
    Inventors: Leif A. Eriksson, Lennart Löfgren
  • DNA encoding canine monomeric CRP and expression vector containing the DNA
    Patent number: 9359416
    Abstract: Pentameric CRP is produced at a high efficiency by transferring DNA, which encodes monomeric CRP, into a silkworm to thereby construct a transgenic silkworm and then collecting and purifying pentameric CRP that is produced by the transgenic silkworm constructed above.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: June 7, 2016
    Assignees: NITTO BOSEKI CO., LTD., NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES
    Inventors: Iwao Kiyokawa, Yuji Arimatsu, Toshihide Miura, Ryo Kojima, Hideki Sezutsu, Keiro Uchino, Isao Kobayashi, Toshiki Tamura
  • DNA vaccines and methods for the prevention of transplantation rejection
    Patent number: 9358277
    Abstract: Methods for preventing, delaying the onset of, or treating rejection of an allograft using a DNA vaccine, where the vaccine can comprise a polynucleotide encoding a pro-apoptotic protein, like BAX and/or a polynucleotide encoding an autoantigen or donor antigen, like secreted glutamic acid decarboxylase 55. Administering one of the DNA vaccines to a transplant recipient, as described herein, can induce a donor specific tolerogenic response.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: June 7, 2016
    Assignee: Loma Linda University
    Inventors: Fengchun Li, Alan P. Escher
  • Compositions and methods for producing emulsions for nuclear magnetic resonance techniques and other applications
    Patent number: 9352057
    Abstract: The disclosure provides, in part, compositions and methods for producing emulsions. In certain embodiments, emulsions of the disclosure can be used for the detection of inflammation and cell tracking using MRI. The disclosure provides, in part, methods for labeling, detecting and quantifying cell members, in vivo. In certain embodiments, emulsions can be used as an artificial blood substitute.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: May 31, 2016
    Assignee: Celsense, Inc.
    Inventors: Eric T. Ahrens, Jelena Janjic
  • Topical cream composition
    Patent number: 9351996
    Abstract: A topical skin cream composition having as one of its main objects to provide a topical skin cream having anti-biotic properties to prevent infection in wounds. In addition the combination of components in the composition help combat the effects of aging as well as help ward off psoriasis.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: May 31, 2016
    Inventor: Sayed Antar
  • Methods of producing hybrid antibodies
    Patent number: 9353394
    Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: May 31, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, George D. Yancopoulos, Margaret Karow, Lynn Macdonald, Sean Stevens, Aris N. Economides, David M. Valenzuela
  • Multi-functional male shaving product
    Patent number: 9333153
    Abstract: A multi-functional, foaming male shaving product comprising of (i) a surfactant blend consisting of an alkyl isethionate and a glyceryl alkanoate, wherein the ratio, by weight of alkyl isethionate to glyceryl alkanoate is between 5:1 to 8:1, (ii) a copolymer of acrylamide and iallyldimethylammonium chloride; (iii) a combination of a yeast extract, an algae extract, an extract of Chondrus crispus, and glucosamine hydrochloride; and (iv) a continuous self-foaming agent containing a volatile hydrofluoroether.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: May 10, 2016
    Assignee: Renuskin, LLC
    Inventors: John Renucci, Susan Goldsberry, Lyndon Garcines
  • Method for treating a neoplastic disorder
    Patent number: 9320757
    Abstract: A method for treating a neoplastic disorder in a subject includes administering to the neoplastic cells a neoplastic cell-sensitizing composition including a poly(ethylene oxide)-poly(propylene oxide) copolymer. The poly(ethylene oxide)-poly(propylene oxide) copolymer can sensitize the neoplastic cells to hyperthermia. Energy can be applied to the neoplastic cells to heat and ablate the cells.
    Type: Grant
    Filed: November 29, 2007
    Date of Patent: April 26, 2016
    Assignee: Case Western Reserve University
    Inventors: Agata Exner, Tianyi Krupka, Brent Weinberg, John Haaga